GET DAILY SIGNALSAurinia Pharmaceuticals (AUPH) Shows Steady Q3 Growth and Raises 2026 Guidance
Key Takeaways
- Aurinia reported third-quarter 2026 total revenue of $83.7 million, up 14% from $73.5 million a year earlier.
- LUPKYNIS net product sales reached $79.4 million, up 12% year over year and still the dominant revenue driver.
- Diluted earnings per share (EPS) came in at $0.23, roughly in line with consensus and flat versus the prior-year quarter.
- Net income was $31.7 million, essentially unchanged from $31.6 million in Q3 2025.
- The company raised its full-year 2026 total revenue guidance to $325 million–$330 million and narrowed net product sales guidance to $310 million–$315 million.
- Aurinia ended the quarter with $486.9 million in cash, cash equivalents, restricted cash and investments.
Earnings Context and Why It Matters
Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company whose lead product, LUPKYNIS (voclosporin), is the first FDA-approved oral therapy for adults with active lupus nephritis (LN) — a serious kidney inflammation caused by the autoimmune disease lupus. Because LUPKYNIS generates the overwhelming majority of revenue, each quarterly report serves as a direct read on commercial execution, market share, and pricing. Q3 2026 also matters because it tests whether the company can sustain double-digit growth while advancing a broader pipeline. Investors closely track net product sales, profitability, cash generation, and management's guidance as key signals for the year ahead. From what I see, these metrics remain central to assessing long-term sustainability.
Reported Results
Aurinia reported total revenue of $83.7 million for the three months ended September 30, 2026, up 14% from $73.5 million in the prior-year period. Net product sales of LUPKYNIS were $79.4 million, up 12% from $70.6 million, while license, collaboration and royalty revenue from its partner Otsuka climbed 54% to $4.3 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Net income was $31.7 million, essentially flat versus $31.6 million a year earlier, and diluted EPS held steady at $0.23. For the nine months ended September 30, 2026, total revenue reached $244.6 million (up 19%), net income rose 35% to $103.5 million, and diluted EPS increased 38% to $0.76. The quarter was broadly in line with Wall Street expectations, with results landing near consensus rather than delivering a notable beat. Using Tickeron’s AI Pattern Search Engine helped confirm the technical setup around these results.
Management raised full-year 2026 total revenue guidance to $325 million–$330 million (from $315 million–$325 million) and narrowed net product sales guidance to $310 million–$315 million. The company closed the quarter with $486.9 million in cash, cash equivalents, restricted cash and investments.
Market Reaction and Investor Sentiment
Despite results that were largely in line with estimates and an upward revision to full-year guidance, AUPH shares pulled back roughly 3% in the session following the October 30 release. The muted-to-negative reaction suggests investors were looking for a clearer beat or more aggressive pipeline catalysts, while lingering concerns around single-product concentration and competitive pressure from newer lupus nephritis therapies continue to weigh on sentiment. The pullback also reflects a market that has already priced in steady LUPKYNIS growth and is now focused on the durability of that growth beyond 2026.
Forward Outlook and Key Factors to Monitor
The raised full-year revenue guidance signals management's confidence in LUPKYNIS demand through year-end, but investors will be watching whether that momentum carries into 2027. The company narrowed its net product sales range to $310 million–$315 million, which implies continued sequential growth driven by patient expansion and adherence in the U.S. market.
On the pipeline front, Aurinia recently initiated PRESERVE, a Phase 4 study evaluating LUPKYNIS in combination with biologic agents such as belimumab, obinutuzumab, or anifrolumab in lupus nephritis. Positive data could strengthen LUPKYNIS's competitive positioning. Separately, the company is advancing aritinercept (AUR200), a dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), as a potential treatment for autoimmune diseases.
Key factors to monitor include the pace of LUPKYNIS prescription growth, Otsuka collaboration revenue, operating expense discipline, and any clinical readouts from the PRESERVE and aritinercept programs. Competition and patent-related dynamics — including the August 2026 settlement with Teva — also remain important considerations for the stock's longer-term trajectory.
Using AI Tools in My Research Process
In my own analysis, I regularly turn to Tickeron’s AI Daily Buy/Sell Signals to track momentum shifts and generate ideas across the biotech space. It provides a quick way to layer technical signals on top of fundamental data like the numbers we just reviewed, helping me stay objective when evaluating names such as AUPH. The platform has become a standard part of how I scan for context around quarterly updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AUPH in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 02, 2026
AUPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 38 cases where AUPH's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
AUPH moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for AUPH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +1.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where AUPH advanced for three days, in 214 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 136 of 165 cases where AUPH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
Bearish Trend Analysis
The 10-day RSI Indicator for AUPH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 23 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AUPH as a result. In 74 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AUPH turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 38 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AUPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 18 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. AUPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.583) is normal, around the industry mean (3.051). P/E Ratio (7.017) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.429) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AUPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which focuses on discovery and development of immunomodulating therapeutics
Industry Biotechnology
Advertisement